Shots:

• The P-Ib trial will be conducted in two parts with Part A assessing the safety, tolerability & PK of NMRA-511 (V1aR antagonist) among healthy elderly individuals (n=~8) and Part B determining the safety, tolerability & efficacy of NMRA-511 (20mg, BID) among individuals (n=~88) with agitation associated with dementia because of AD
• The 1EP of the study includes a change in the Cohen-Mansfield Agitation Inventory total score at wk.8. Topline data is anticipated in H2’25
• Neumora's concluded P-Ia single ascending dose (SAD)/multiple ascending dose (MAD) trial of NMRA-511 (5,10, 15, 20 & 40 mg) among healthy adults (n=92) found the drug well tolerated without any SAEs. Data is expected at upcoming conferences

Ref: Neumora Therapeutics | Image: Neumora Therapeutics

Related News:- Takeda and AC Immune Collaborate for ACI-24.060 to Treat Alzheimer’s Disease

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com